St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales
This article was originally published in The Gray Sheet
Executive Summary
St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure
You may also be interested in...
Guidant Surveys Resynch Pool: Doc Loyalty, Sales Presence Will Rule The Day
Cardiac resynchronization defibrillator procedures, by their inherent complexity, will foster loyalty to a single manufacturer's CRT-D devices, Guidant President and CEO Ron Dollens asserted at JPMorgan's annual healthcare conference in San Francisco Jan. 12
Guidant Surveys Resynch Pool: Doc Loyalty, Sales Presence Will Rule The Day
Cardiac resynchronization defibrillator procedures, by their inherent complexity, will foster loyalty to a single manufacturer's CRT-D devices, Guidant President and CEO Ron Dollens asserted at JPMorgan's annual healthcare conference in San Francisco Jan. 12
St. Jude Resynchronization ICD Enrollment Trimmed By 150 Patients
St. Jude continues to project that its Epic HF resynchronization ICD will not reach the U.S. market until early 2004, despite FDA permission to reduce the required sample size of the pivotal RHYTHM study